[Skip to Content]
[Skip to Content Landing]
August 8, 2007

Hormone Therapy and Cardiovascular Risk

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2007;298(6):623-625. doi:10.1001/jama.298.6.623-a

To the Editor: Dr Rossouw and colleagues1 analyzed postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause; they used combined data for conjugated equine estrogen (CEE) therapy and CEE plus medroxyprogesterone acetate (CEE + MPA) from the Women's Health Initiative (WHI). The hazard ratios (HRs) for coronary heart disease (CHD) based on years since menopause were 0.76 (<10 years), 1.10 (10-19 years), and 1.28 (≥20 years) (P for trend = .02). The corresponding values for CEE were 0.48, 0.96, and 1.12 (P for trend = .15); for CCE + MPA the estimates were 0.88, 1.23, and 1.66 (P for trend =.05).